ERBB2 and ductal breast carcinoma in situ: It would be interesting to investigate whether HER2-positive primary DCIS is more frequently observed in patients with ipsilateral clonally related invasive recurrences, regardless of the HER2 status of this recurrence, since the main purpose of surgical DCIS treatment is to prevent IBC development, and thus, risk of systemic disease and death [1].